Our datasets identify a set of early response transcription factors that are upregulated by ALKAL2 stimulation in an ALK‐dependent manner, and these core transcription factors are also highly responsive to inhibition of ALK in ALK‐driven NB cell lines that harbour ALK activating mutations (Van den Eynden et al, 2018). The gene discussed is ALKAL2; the disease is neuroblastoma.